ASH 2023 | What’s on the horizon for the treatment of MPNs?
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives her thoughts on what data is anticipated in the treatment of myeloproliferative neoplasms (MPNs). She mentions combinations of ruxolitinib with venetoclax or pelabresib, novel agents in the field, and the targeting of calreticulin with antibodies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
A couple of years brought us to finally having the top line results of especially two large Phase III studies -the combination of ruxolitinib plus navitoclax versus ruxolitinib placebo, and then BET inhibitor pelabresib/ruxolitinib versus rux/placebo. So everybody is expecting those results, kind of like seeing excellent spleen responses but questionable symptoms, so we are all eagerly looking out for how this data will look, how are they going to fill in, and what’s going to happen to these drugs? That is really exciting...
A couple of years brought us to finally having the top line results of especially two large Phase III studies -the combination of ruxolitinib plus navitoclax versus ruxolitinib placebo, and then BET inhibitor pelabresib/ruxolitinib versus rux/placebo. So everybody is expecting those results, kind of like seeing excellent spleen responses but questionable symptoms, so we are all eagerly looking out for how this data will look, how are they going to fill in, and what’s going to happen to these drugs? That is really exciting.
And lots of novel compounds or novel preclinical ideas. The role of, for example, NF-kappaB, TGFbeta mutations or inhibitors, some newer drugs or pathways that we could block. And of course very exciting calreticulin, the calreticulin monoclonal antibody, which is the original, the naked one, as well as the the bispecific with the CD3, which is a poster at ASH, is really, really getting all of us into excitement where we may finally find calreticulin-directed therapy for ET and MF patients and hopefully, hopefully, which I keep saying, separate the calreticulin mutated versus the rest of the MPNs and completely shape the field into the near future.
Read more...
Disclosures
Board of Directors/Advisory Committee: MorphoSys US
